The U.S. drug maker offered Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) shareholders $24.50 a share, or $3.85 billion, for the developer of hepatitis C drugs. That’s almost quadruple the stock’s average unaffected price over the previous 20 days, the highest premium on record for any health care deal of at least $100 million, according to data compiled by Bloomberg. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) stock performance was -0.55% … Continue reading Active Movers: Idenix Pharmaceuticals Inc (NASDAQ:IDIX), Groupon Inc (NASDAQ:GRPN), Twenty-First Century Fox Inc (NASDAQ:FOXA), Sirius XM Holdings Inc. (NASDAQ:SIRI), DryShips Inc. (NASDAQ:DRYS)